共 65 条
- [1] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma[J]. NATURE MEDICINE, 2018, 24 (11) : 1649 - +Amaria, Rodabe N.Reddy, Sangeetha M.Tawbi, Hussein A.Davies, Michael A.Ross, Merrick, IGlitza, Isabella C.Cormier, Janice N.Lewis, CarolHwu, Wen-JenHanna, EhabDiab, AdiWong, Michael K.Royal, RichardGross, NeilWeber, RandalLai, Stephen Y.Ehlers, RichardBlando, JorgeMilton, Denai R.Woodman, ScottKageyama, RobinWells, Daniel K.Hwu, PatrickPatel, Sapna P.Lucci, AnthonyHessel, AmyLee, Jeffrey E.Gershenwald, JeffreySimpson, LaurenBurton, Elizabeth M.Posada, LibertyHaydu, LaurenWang, LinghuaZhang, ShaojunLazar, AlexanderjHudgens, Courtney W.Gopalakrishnan, VancheswaranReuben, AlexandreAndrews, Miles C.Spencer, Christine N.Prieto, VictorSharma, PadmaneeAllison, JamesTetzlaff, Michael T.Wargo, Jennifer A.
- [2] Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial[J]. LANCET ONCOLOGY, 2018, 19 (02) : 181 - 193Amaria, Rodabe N.Prieto, Peter A.Tetzlaff, Michael T.Reuben, AlexandreAndrews, Miles C.Ross, Merrick J.Glitza, Isabella C.Cormier, JaniceHwu, Wen-JenTawbi, Hussein A.Patel, Sapna P.Lee, Jeffrey E.Gersbenwaid, Jeffrey E.Spencer, Christine N.Gopalakrishnan, VancheswaranBassett, RolandSimpson, LaurenMouton, RosalindHudgens, Courtney W.Zhao, LiZhu, HaifengCooper, Zachary A.Wani, KhalidaLazar, AlexanderHwu, PatrickDiab, AdiWong, Michael K.McQuade, Jennifer L.Royal, RichardLucci, AnthonyBurton, Elizabeth M.Reddy, SangeethaSharma, PadmaneeAllison, JamesFutreal, Phillip A.Woodman, Scott E.Davies, Michael A.Wargo, Jennifer A.
- [3] Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial[J]. LANCET ONCOLOGY, 2020, 21 (11) : 1465 - 1477Ascierto, Paolo A.Del Vecchio, MicheleMandala, MarioGogas, HelenArance, Ana M.Dalle, StephaneCowey, C. LanceSchenker, MichaelGrob, Jean-JacquesChiarion-Sileni, VannaMarquez-Rodas, IvanButler, Marcus O.Maio, MicheleMiddleton, Mark R.de la Cruz-Merino, LuisArenberger, PetrAtkinson, VictoriaHill, AndrewFecher, Leslie A.Millward, MichaelKhushalani, Nikhil, IQueirolo, PaolaLobo, Mauricede Pril, VeerleLoffredo, JohnLarkin, JamesWeber, Jeffrey
- [4] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial[J]. LANCET ONCOLOGY, 2016, 17 (09) : 1248 - 1260Ascierto, Paolo A.McArthur, Grant A.Dreno, BrigitteAtkinson, VictoriaLiszkay, GabrielleDi Giacomo, Anna MariaMandala, MarioDemidov, LevStroyakovskiy, DaniilThomas, Lucde la Cruz-Merino, LuisDutriaux, CarolineGarbe, ClausYan, YibingWongchenko, MatthewChang, IlsungHsu, Jessie J.Koralek, Daniel O.Rooney, IsabelleRibas, AntoniLarkin, James
- [5] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116Atkins, MBLotze, MTDutcher, JPFisher, RIWeiss, GMargolin, KAbrams, JSznol, MParkinson, DHawkins, MParadise, CKunkel, LRosenberg, SA
- [6] Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma[J]. NATURE MEDICINE, 2018, 24 (11) : 1655 - +Blank, Christian U.Rozeman, Elisa A.Fanchi, Lorenzo F.Sikorska, Karolinavan de Wiel, BartKvistborg, PiaKrijgsman, Oscarvan den Braber, MarlousPhilips, DaisyBroeks, Annegienvan Thienen, Johannes, VMallo, Henk A.Adriaansz, Sandrater Meulens, SylviaPronk, Loes M.Grijpink-Ongering, Lindsay G.Bruining, AnnemarieGittelman, Rachel M.Warren, Sarahvan Tinteren, HarmPeeper, Daniel S.Haanen, John B. A. G.van Akkooi, Alexander C. J.Schumacher, Ton N.
- [7] A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4[J]. NATURE, 1987, 328 (6127) : 267 - 270BRUNET, JFDENIZOT, FLUCIANI, MFROUXDOSSETO, MSUZAN, MMATTEI, MGGOLSTEIN, P
- [8] Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 391 - +Callahan, Margaret K.Kluger, HarrietPostow, Michael A.Segal, Neil H.Lesokhin, AlexanderAtkins, Michael B.Kirkwood, John M.Krishnan, SubaBhore, RafiaHorak, ChristineWolchok, Jedd D.Sznol, Mario
- [9] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516Chapman, Paul B.Hauschild, AxelRobert, CarolineHaanen, John B.Ascierto, PaoloLarkin, JamesDummer, ReinhardGarbe, ClausTestori, AlessandroMaio, MicheleHogg, DavidLorigan, PaulLebbe, CelesteJouary, ThomasSchadendorf, DirkRibas, AntoniO'Day, Steven J.Sosman, Jeffrey A.Kirkwood, John M.Eggermont, Alexander M. M.Dreno, BrigitteNolop, KeithLi, JiangNelson, BettyHou, JeannieLee, Richard J.Flaherty, Keith T.McArthur, Grant A.
- [10] Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2[J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (04) : 888 - 892Clark, Joseph, ICurti, BrendanDavis, Elizabeth J.Kaufman, HowardAmin, AsimAlva, AjjaiLogan, Theodore F.Hauke, RalphMiletello, Gerald P.Vaishampayan, UlkaJohnson, Douglas B.White, Richard L.Wiernik, Peter H.Dutcher, Janice P.